More about High-Yield Cash Accounts with M1
Brokerage Accounts
Retirement Accounts
Other Accounts
Quotes are delayed by 15 minutes.
1D
1W
1M
3M
6M
YTD
1Y
2Y
5Y
ALL
Market cap
$4.76B
EPS
-9.43
P/E ratio
--
Price to sales
50.44
Dividend yield
--
Beta
2.867055
Previous close
$105.60
Today's open
$108.95
Day's range
$99.52 - $110.56
52 week range
$41.50 - $166.48
show more
CEO
Bob Ragusa
Employees
910
Headquarters
Sunnyvale, CA
Exchange
Nasdaq Global Select
Shares outstanding
44962171
Issue type
Common Stock
Healthcare
Medical Diagnostics & Screening
GRAIL, Inc. (GRAL) Presents at 2026 UBS Global Healthcare Conference Transcript
GRAIL, Inc. ( GRAL ) 2026 UBS Global Healthcare Conference November 10, 2026 11:00 AM EST Company Participants Aaron Freidin - CFO & Head of Corporate Development Conference Call Participants Douglas Schenkel - UBS Investment Bank, Research Division Presentation Douglas Schenkel UBS Investment Bank, Research Division All right. Good morning.
Seeking Alpha • Nov 10, 2026

GRAIL Q3 Earnings Call Ties FDA Review to Pricing and Sales Growth
GRAL is cutting Galleri prices to boost adoption ahead of an expected early 2027 FDA decision, even as pricing pressure weighs on revenue growth and margins.
Zacks Investment Research • Nov 5, 2026

Artisan Global Equity Fund Q3 2026 Portfolio Review
In Q3 2026, the portfolio underperformed its benchmark, the MSCI All Country World Index. On a positive note, our stock selection in the health care sector led to significant outperformance relative to those in the benchmark. Numerous portfolio moves were made during the quarter, but our focus remained on our three main investment themes: electrification, financials and aerospace and defense.
Seeking Alpha • Nov 5, 2026

Grail Tumbles After DNA-Testing Outfit Misses Sales Expectations
Grail stock fell late Wednesday after the next-generation sequencing company reported light third-quarter sales.
Investors Business Daily • Nov 4, 2026

What GRAIL (GRAL) Said on Its Q3 Earnings Call
GRAIL NASDAQ: GRAL reported 4% revenue growth for the third quarter of 2026 as higher testing volumes were offset in part by lower prices, and said it expects a U.S. regulatory decision on its Galleri cancer screening test by early in the first quarter of 2027.
MarketBeat • Nov 5, 2026

GRAIL, Inc. (GRAL) Q3 2026 Earnings Call Transcript
GRAIL, Inc. (GRAL) Q3 2026 Earnings Call Transcript
Seeking Alpha • Nov 5, 2026

GRAIL Reports Third Quarter 2026 Financial Results
FDA Advisory Committee Voted in Favor of Approval of GRAIL's Galleri Multi-Cancer Early Detection Test Q3 Galleri ® Test Volume Increased ~24% to More Than 56,000 Year-Over-Year, Year-to-Date Test Volume Increased ~36% to More Than 174,000 Q3 Galleri Revenue Grew 14% Year-Over-Year to $37.3 Million SUNNYVALE, Calif., Nov. 4, 2026 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today reported business and financial results for the third quarter of 2026.
PRNewsWire • Nov 4, 2026

GRAIL Q3 Earnings Ahead: Galleri Test Adoption to Drive Growth
GRAL's Q3 earnings should have benefited from rising Galleri test adoption, expanding digital health partnerships and growing clinical evidence of cancer detection.
Zacks Investment Research • Oct 29, 2026

GRAIL to Present at the UBS Global Healthcare Conference
SUNNYVALE, Calif., Oct. 27, 2026 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced that company management will present at the UBS Global Healthcare Conference in Palm Beach, FL on Tuesday, Nov. 10 at 11:00 a.m.
PRNewsWire • Oct 27, 2026

5 Beaten-Down Growth Stocks Trading Like Value Plays as Cash Chases Mega-Caps
The S&P 500 recently sat just 2.5% below its all-time high. Look past the index, though, and the picture gets uglier.
MarketBeat • Oct 26, 2026

¹ Disclosures

Open an M1 investment account to buy and sell GRAIL Inc. commission-free¹. Build wealth for the long term using automated trading and transfers.